Dr Deborah Gill is a translational scientist with over 20 years of experience in the field of gene therapy.Deborah undertook a Ph.D. at the University of Warwick where she discovered the defining member of the ABC Superfamily of proteins, which was reported in Nature.
Following post-doctoral work she became an Assistant Scientist at the Weatherall Institute of Molecular Medicine in Oxford, undertaking two clinical trials to evaluate non-viral gene therapy for Cystic Fibrosis in the mid-1990s.
She is now a Research Lecturer at the University of Oxford and Co-Director of the Gene Medicine Research Group, focused on translating research into lung therapeutics.
As part of the UK Gene Therapy Consortium's clinical programme Deborah is responsible for the manufacture and procurement of the gene therapy product for clinical trials.
Dr Stephen Hyde has a D.Phil. in Biochemistry from the University of Oxford where he studied the structure and function of ABC proteins, including the protein responsible for Cystic Fibrosis.
During post-doctoral research at Oxford Stephen was the first to demonstrate that gene transfer could correct the Cystic Fibrosis defect in transgenic mice.
This led to an extensive pre-clinical and clinical programme of gene therapy. He has acted as a specialist advisor on the clinical safety of gene therapy vectors to both the Department of Health's Gene Therapy Advisory Committee and the Committee on the Safety of Medicines, and has advised the Department of Health's National Translational Cancer Research Network on the procurement of gene transfer vectors.
Stephen is now a Research Lecturer at Oxford University and co-directs the Gene Medicine Research Group developing gene transfer vectors for clinical application and leads on Regulatory Affairs within the UK Cystic Fibrosis Gene Therapy Consortium.
Dr Ian Pringle is a postdoctoral scientist and has worked for the UK CF Gene Therapy Consortium for a number of years. He has a BSc (Applied Molecular Biology) from the University of Aberdeen and a D.Phil (Biochemistry) from Trinity College, Oxford.
As a molecular biologist, Ian's main focus in the Consortium has been the development of gene therapy vectors. He had a leading role in the creation of the Consortium's clinical trial product (GL67A/pGM169) and today he continues to develop and test novel vectors.
He is a previous winner of the British Society for Gene & Cell Therapy's Outstanding Young Scientist award.
Wolfson College, Funded by the Malaysian Government.
Lady Margaret Hall, funded by the RDM Scholarship Programme.
In the Gene Medicine research group, Joost investigates the opportunities for lifelong expression of therapeutic genes to correct genetic liver diseases.
Recent gene therapy clinical trials have shown that the duration of expression of therapeutic genes (which ideally would be lifelong) leaves much to be desired, causing the therapeutic effect to be only temporary. Joost is investigating two possible solutions to circumvent this issue. On the one hand, he is trying to avert the antibody response that the body raises to fight the viruses used for gene therapy to make sure that those antibodies can no longer prevent the viruses from infecting the targeted liver cells. The second part of his project concerns the possibility to have a single gene therapy dose exerting a lifelong effect by integrating the therapeutic gene directly into a precise spot in the genome.
Before joining the University of Oxford, Joost did a master's degree in Cell and Gene Therapy at University College London during which he worked in the lab of Prof Stephen Hart on CRISPR/Cas9 mediated knock-down of ENaCa in Cystic Fibrosis. He has completed his bachelor's degree at Maastricht University.